Noroplex (Dimethyl Fumarate)

Dimethyl fumarate, the active ingredient in Noroplex, is an oral disease‑modifying therapy presented as an oral tablet for oral use. It exerts anti‑inflammatory and immunomodulatory actions and is employed to treat relapsing forms of multiple sclerosis as well as moderate‑to‑severe plaque psoriasis in adult patients.

GNH USA supplies Noroplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for global healthcare providers.

Dimethyl fumarate modulates the Nrf2 pathway and is used in inflammatory and autoimmune disease management.

- Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows the accumulation of disability over time. - Active secondary progressive multiple sclerosis: decreases inflammatory disease activity in patients with active disease, contributing to reduced relapse risk. - Moderate‑to‑severe plaque psoriasis: improves skin lesion severity scores and reduces the extent of erythema and scaling.

Dimethyl fumarate is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Flushing: transient warmth and redness, often mitigated by taking with food. - Gastrointestinal upset: includes nausea, abdominal discomfort, or diarrhea. - Lymphopenia: mild reduction in peripheral lymphocyte counts.

Serious or Rare Side Effects: - Severe lymphopenia: marked decrease in lymphocytes increasing infection risk. - Hepatic injury: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare opportunistic brain infection.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor lymphocyte counts: perform baseline and periodic CBC to detect lymphopenia. - Assess liver function: check hepatic enzymes before starting and during treatment. - Avoid use in active infection: postpone therapy until infection is resolved. - Pregnancy considerations: limited data; weigh potential benefits against unknown risks. - Educate about flushing: advise taking with food to reduce severity. - Store below 25°C: keep in the original pack, protect from moisture.

Dimethyl fumarate may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live attenuated vaccines: increased risk of infection; avoid concurrent administration. - Concurrent immunosuppressants (e.g., azathioprine, methotrexate): additive immunosuppression may heighten infection risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption; separate dosing by at least 2 hours. - Other Nrf2 activators (e.g., bardoxolone): potential additive pharmacodynamic effects; monitor clinical response. - CYP inducers (e.g., rifampin): may lower plasma concentrations; consider therapeutic monitoring.